Filter by: Subject

Filter by: Subject

Results Per Page:

Positron emission tomography (PET) (7)
SDG-03: Good health and well-being (5)
Prostate carcinoma (4)
Prostate-specific membrane antigen (PSMA) (4)
PSA response (3)
225Ac-PSMA-617 (2)
68Ga-PSMA (2)
Cervical cancer (2)
Computed tomography (CT) (2)
Hypoxia (2)
Immunohistochemistry (2)
Metastatic castration-resistant prostate cancer (mCRPC) (2)
PET/CT (2)
Positron emission tomography/computed tomography (PET/CT) (2)
Therapy response (2)
Tuberculosis (TB) (2)
18F-FDG (1)
225Ac-PSMA (1)
68Ga-citrate (1)
68Ga-Nitroimidazole (1)
[68Ga]Ga-FAPI PET/CT (1)
Androgen deprivation treatment (ADT) (1)
Behandlung (1)
Benign vs. malignant (1)
Bins (1)
Bioassay (1)
Biomaterials (1)
Black South-African (BSAs) (1)
Blood–brain barrier (BBB) (1)
Bone SPECT-CT (1)
Breast cancer (1)
Carcinoma, squamous cell (1)
Characterization (1)
Chelation (1)
Chemical analysis (1)
Chemical modification (1)
Chromatography (1)
Computerized tomography (CT) (1)
Cryptic peptides (1)
Dichroism (1)
Drug products (1)
FAPI tumor volume (FAPI-TV) (1)
FDG-PET (1)
FDG-PET imaging (1)
Fludeoxyglucose (FDG) (1)
Fluorodeoxyglucose F18 (1)
Fluorodeoxyglucose-positron emission tomography (FDG PET) (1)
Functional characterization (1)
Gastro-intestinal cancer (1)
GHR bioassay (1)
Growth hormone receptor (GHR) (1)
Health sciences article SDG-03 (1)
Highly active antiretroviral therapy (HAART) (1)
HIV infection (1)
HIV infections (1)
Human growth hormone (1)
Human immunodeficiency virus (HIV) (1)
Hypoxia inducible factor-1 (HIF-1) (1)
Hypoxia-inducible factor-1alpha (HIF-1) (1)
Hypoxic tumor volume (HTV) (1)
Immunohistochemistry (IHC) (1)
Inherent complexity (1)
Intra-tumoral heterogeneity (1)
Isomers (1)
Lipodystrophy (1)
Logistic binomial regression (1)
Loosening (1)
Lumbar fusion (1)
Lung lesions (1)
Mass spectrometry (1)
Medical imaging (1)
Metabolic tumor volume (MTV) (1)
Metastatic hormone-sensitive prostate carcinoma (mHSPC) (1)
Metastatic prostate carcinoma (1)
Multiple substitutions (1)
Native mass spectrometries (1)
Native MS (1)
Non-prostate carcinoma (1)
Overall survival (OS) (1)
Patient management (1)